Do MAT Clinics Make More Money by Keeping People on Medication?

The Elephant in the Room

Many patients wonder whether addiction treatment clinics have a financial incentive to keep people on medication.

That question can feel uncomfortable to ask. Patients may worry that it sounds accusatory or that their provider will take it personally. But it is a reasonable question. Any treatment model that involves ongoing visits and ongoing payment deserves to be discussed honestly.

At Shoreline, we think patients should be able to ask direct questions about their care. That includes questions about whether a medication is still helping, whether it is still needed, and whether the treatment plan is being continued for the right reasons.

Yes, Ongoing Treatment Creates Ongoing Revenue

The honest answer is that medical offices are generally paid when they provide care. Addiction treatment is no different.

If a patient is seen regularly for buprenorphine, Suboxone, naltrexone, or other medication treatment, the clinic is usually paid for those visits. That may be through insurance, self-pay, or another payment arrangement.

But the fact that care is paid for does not automatically mean the care is inappropriate. Most medical care works this way. A doctor who treats diabetes is paid for follow-up visits. A psychiatrist is paid for medication management. A cancer center is paid for chemotherapy. A cardiologist is paid to manage heart disease.

The ethical question is not simply, “Does the clinic get paid?” The ethical question is, “Is the treatment medically appropriate, helpful, and being reassessed over time?”

How This Is Similar to Other Areas of Medicine

In many areas of medicine, long-term treatment is normal.

A patient with high blood pressure may take medication for years. A patient with diabetes may need long-term follow-up, lab monitoring, and medication adjustments. A patient receiving cancer treatment may have repeated visits, infusions, imaging, and specialist care. These treatments generate revenue for the healthcare system, but that does not mean they are unnecessary.

The same basic principle applies to addiction medicine. Opioid use disorder and alcohol use disorder are often chronic, relapsing conditions. For many people, ongoing medication treatment reduces risk and supports stability. A person may be doing well partly because the medication is working.

In that sense, long-term addiction treatment should not be viewed as a failure. It may be appropriate, evidence-based medical care.

How Addiction Treatment Is Different

At the same time, addiction treatment is different from many other areas of medicine.

Patients seeking addiction treatment are often in a vulnerable position. They may be afraid of withdrawal, worried about relapse, dealing with shame, or trying to rebuild trust with family, work, or the legal system. Some patients have had negative experiences with treatment programs in the past. Others may be paying out of pocket and wondering whether every visit is truly necessary.

There is also a unique emotional weight around medications like buprenorphine. Even when buprenorphine is helping, patients may worry that they have “traded one thing for another.” Some people feel pressure from family, recovery communities, or even themselves to stop medication before they are ready.

That is why addiction treatment requires extra transparency. Providers should not use fear to keep patients in treatment. They should not dismiss a patient’s desire to eventually taper. They should also not pressure patients to stop medication when continuing treatment is the safer choice.

Long-Term Medication Is Not the Same as Over-Treatment

Many people benefit from staying on buprenorphine, Suboxone, or naltrexone long term.

For some patients, medication reduces cravings, prevents return to use, lowers overdose risk, and helps them rebuild a stable life. It may support work, parenting, relationships, sleep, mental health, and a sense of normal daily routine.

When a medication is helping someone stay alive and function better, continuing it may be good medicine.

But long-term treatment should not become automatic treatment. A patient should not feel like the plan is simply “come back every month forever” without any discussion of goals, progress, side effects, or future options.

The issue is not whether someone stays on medication for a long time. The issue is whether the decision is thoughtful, transparent, and individualized.

The Evidence Generally Favors Longer Treatment

It is also important to be honest about the medical evidence: for opioid use disorder, the data generally favors longer-term treatment with buprenorphine over short-term treatment followed by tapering.

That does not mean every person must stay on medication forever. It does mean that stopping buprenorphine is not automatically a sign of success, and staying on buprenorphine is not automatically a sign of failure.

For many people, buprenorphine is part of why things are going well. When someone is stable, working, parenting, avoiding illicit opioids, and feeling more in control, it can be tempting to say, “Maybe I do not need this anymore.” Sometimes that may eventually be true. But sometimes the medication is one of the reasons that stability exists.

A good provider should be honest about that. They should explain why continuing medication may be recommended, especially if stopping could increase the risk of cravings, relapse, withdrawal, or overdose.

At the same time, evidence should not be used to shut down the conversation. A patient can understand that long-term treatment is often safer and still want to talk about whether tapering might make sense someday.

For a deeper discussion of this topic, see our related page: How Long Should I Be on Buprenorphine?

The Real Red Flag: No One Ever Reassesses the Plan

The red flag is not simply that a clinic recommends ongoing medication. There are many good reasons to continue medication treatment.

The bigger concern is when the plan is never reassessed.

If every visit feels like “refill, urine test, payment, repeat,” patients may reasonably wonder whether anyone is still thinking carefully about the bigger picture.

Good addiction treatment should periodically revisit questions like:

• Are you still benefiting from the medication?

• Are you having side effects?

• Are cravings controlled?

• Are there any signs of return to use or increased risk?

• Are you functioning better in daily life?

• Do you want to continue the current plan?

• Do you want to talk about tapering someday?

• What would make tapering safer or riskier right now?

These questions do not need to be answered the same way at every visit. But they should not disappear from the treatment relationship.

Our Approach at Shoreline

At Shoreline, we do not measure success by whether someone stays on medication forever.

We measure success by whether treatment is helping someone live a safer, more stable, more functional life.

For some patients, that means long-term medication treatment. For others, it may eventually mean a careful taper. For many people, the goal changes over time as life becomes more stable and recovery becomes stronger.

We are comfortable with both conversations: continuing medication when it is helping, and thoughtfully discussing tapering when the time is right.

The decision should be made with honesty, medical guidance, and respect for the patient’s goals — not fear, shame, or autopilot care.